German DES
This article was originally published in The Gray Sheet
Executive Summary
FDA already has met with Göttingen-based Avontec and Berlin-based Biotronik to discuss a next-generation drug-eluting stent being developed by both firms under a deal announced May 20. The Biotronik stent will use Avontec's proprietary decoy oligonucleotide to prevent in-stent restenosis. The FDA meeting clarified the companies' joint clinical development strategy, according to Avontec...